Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. It is developing various products for treating solid tumors, including AB928, an adenosine receptor antagonist that is in Phase I clinical trial; AB680, a CD73 inhibitor; AB122, an anti-PD-1 antibody that is Phase I clinical trial; and AB154, an anti-TIGIT antibody. The company was founded in 2015 and is headquartered in Hayward, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:RCUS
CUSIPN/A
Phone650-489-9000
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding Shares44,450,000
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) issued its quarterly earnings results on Wednesday, May, 9th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.88) by $0.49. The company had revenue of $1.25 million for the quarter, compared to the consensus estimate of $1.30 million. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
3 analysts have issued 1-year price objectives for Arcus Biosciences' stock. Their predictions range from $18.00 to $21.00. On average, they anticipate Arcus Biosciences' share price to reach $19.00 in the next twelve months. View Analyst Ratings for Arcus Biosciences.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Ironwood Pharmaceuticals (IRWD), Ascendis Pharma A/S (ASND), Portola Pharmaceuticals (PTLA), The Medicines (MDCO), Emergent Biosolutions (EBS), Evotec (EVTCY), TESARO (TSRO), OPKO Health (OPK), Intercept Pharmaceuticals (ICPT), Clovis Oncology (CLVS), Enanta Pharmaceuticals (ENTA), Xencor (XNCR), Akcea Therapeutics (AKCA), Arena Pharmaceuticals (ARNA) and Global Blood Therapeutics (GBT).
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Mr. Terry Rosen Ph.D., Co-Founder, CEO & Director (Age 58)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 60)
- Ms. Jennifer Jarrett M.B.A., Chief Bus. Officer & CFO (Age 47)
- Mr. Steven Chan, VP of Fin., Corp. Controller & Principal Accounting Officer (Age 46)
- Dr. Stephen Young Ph.D., VP of Technology (Age 49)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.
When does Arcus Biosciences' lock-up period expire?
Arcus Biosciences' lock-up period expires on Tuesday, September 11th. Arcus Biosciences had issued 8,000,000 shares in its public offering on March 15th. The total size of the offering was $120,000,000 based on an initial share price of $15.00. After the expiration of Arcus Biosciences' lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company will be lifted.
Has Arcus Biosciences been receiving favorable news coverage?
News headlines about RCUS stock have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Arcus Biosciences earned a coverage optimism score of 0.25 on Accern's scale. They also gave news articles about the company an impact score of 45.17 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future.
Who are Arcus Biosciences' major shareholders?
Arcus Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Foresite Capital Management III LLC (7.75%), BVF Inc. IL (2.98%), Foresite Capital Management IV LLC (1.46%), Board of Trustees of The Leland Stanford Junior University (1.47%), Lord Abbett & CO. LLC (0.68%) and Artal Group S.A. (0.71%). Company insiders that own Arcus Biosciences stock include Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.
Which institutional investors are buying Arcus Biosciences stock?
RCUS stock was acquired by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, BVF Inc. IL, Foresite Capital Management IV LLC, Board of Trustees of The Leland Stanford Junior University, Lord Abbett & CO. LLC, Artal Group S.A., Millennium Management LLC and JBF Capital Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $15.45.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $712.16 million.
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 650-489-9000 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
